Recent Press Releases

PhRMA Response to Introduction of Senate Patent Bill

WASHINGTON, D.C. (April 29, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Robert Zirkelbach issued the following statement: "The Pharmaceutical...

Teva Provides Additional Detail on Proposed Acquisition of Mylan

Files Updated Investor Presentation Reiterates Compelling Strategic and Financial Benefits for Teva and Mylan Stockholders Highlights Strength of Teva's Business, Pipeline, Leadership and...

Mylan Launches Gilead Sciences' Sovaldi® Tablets in India

POTTERS BAR, England and HYDERABAD, India, May 4, 2015 /PRNewswire/ -- 

Lilly Releases Corporate Responsibility, Global Health Reports

Reports provide updates on economic, environmental, and social performance, as well as efforts to improve health and reduce hunger in vulnerable communities around the world

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

30 April 2015 Issued: Thursday 30 April 2015, London, UK, and South San Francisco, CA, USA – LSE Announcement GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today...

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc

Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma

Joint FDA Advisory Committee to Review Phase 3 Data for a Potential First-in-Class Oncolytic Immunotherapy

THOUSAND OAKS, Calif.,

Johnson & Johnson to Participate in the 2015 Deutsche Bank 40th Annual Health Care Conference

NEW BRUNSWICK, N.J., April 30, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US 30 April 2015 Issued: Thursday 30 April 2015, London, UK, and South San Francisco, CA, USA – LSE...

Jeff Poulton Appointed Shire Chief Financial Officer and Joins Board of Directors

Dublin, Ireland– April 30, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Jeff Poulton as Chief Financial Officer (CFO) and member of the Executive Committee. Jeff...

Shire delivers strong revenue growth and cash generation; 20% increase in Non GAAP earnings per ADS

Continued advancement toward goal of becoming a leading global biotechnology company April 30, 2015 – Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to March...

Teva Reports First Quarter 2015 Results

Revenues of $5.0 billion, in line with the first quarter of 2014. Organic revenue growth of 8% excluding the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants. ...

Teva Sends Letter to Mylan Board

Reiterates Commitment to Engaging with Mylan Board and Consummating Transaction JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced...

Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis

Sanofi growth driven by Genzyme and Merial Group sales(3) increased 2.4% (+12.3% on a reported basis) to €8,810 million Slightly lower Diabetes sales (-3.2%) reflects expected pricing impact...

Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE(R)

NEW BRUNSWICK, N.J., April 29, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the United States Patent and Trademark Office (PTO) regarding...

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

Application includes CheckMate -066, a clinical trial of Opdivo vs. dacarbazine chemotherapy in patients who had not received prior therapy CheckMate -066 marked the first time that a PD-1 immune...

Amgen Announces FDA Advisory Committee Meeting To Review Repatha™ (Evolocumab) As A Treatment For High Cholesterol

THOUSAND OAKS, Calif., April 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Endo

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results

04/29/2015 SEPARATELY, VALEANT ANNOUNCES CFO SUCCESSION PLAN AND ADDITIONAL EXECUTIVE APPOINTMENT LAVAL, Quebec, April 29, 2015 /PRNewswire/ -- 2015 First Quarter Results Total Revenue $2.2...